Dupixent vs Stelara
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Dupixent | US Stelara | |
|---|---|---|
| Generic name | dupilumab | ustekinumab |
| Drug class | IL-4/IL-13 Inhibitor (Biologic) | IL-12/IL-23 Inhibitor (Biologic) |
| Treats | Eczema, asthma, nasal polyps | Psoriasis, Crohn's disease, ulcerative colitis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Sanofi/Regeneron | Janssen |
| Year approved | 2017 | 2009 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $390M | $130M |
| Common side effects | Injection site reactions, Eye inflammation (conjunctivitis), Cold sores, Eosinophilia | Serious infections, Headache, Fatigue, Injection site reactions |
Frequently asked questions
Is Dupixent or Stelara better?
Neither is universally "better." Dupixent (dupilumab) and Stelara (ustekinumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dupixent and Stelara?
Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron, while Stelara is a IL-12/IL-23 Inhibitor (Biologic) made by Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.